IP Library Granted Patent US 8,945,873
Granted Patent B2
US 8,945,873 · App. 13/782,671 · Granted Feb 3, 2015

Polynucleotides encoding Notch receptor antibodies

Inventors: Austin L. Gurney (San Francisco, CA); Timothy Charles Hoey (Hillsborough, CA); Edward Thein Htun van der Horst (Palo Alto, CA); Aaron Ken Sato (Burlingame, CA); Yuan Ching Liu (Fremont, CA); Maureen Fitch Bruhns (San Mateo, CA); John A. Lewicki (Los Gatos, CA)
Assignee: OncoMed Pharmaceuticals, Inc.
C07K16/30C07K16/28A61K39/39558A61K45/06C07K16/462C07K16/464C07K16/22C07K14/435C12N15/63C12N15/79A61K2039/505C07K2316/96C07K2317/56C07K2317/732C07K2317/734
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,945,873
App. No.
13/782,671
Granted
Feb 3, 2015
Kind
B2
Abstract

The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.

Claims (40)

1. An isolated polynucleotide encoding an antibody that specifically binds human NOTCH2 and/or NOTCH3, wherein the antibody comprises:

(a) a heavy chain CDR1 comprising SSSGMS (SEQ ID NO:5), a heavy chain CDR2 comprising VIASSGSNTYYADSVKG (SEQ ID NO:6), and a heavy chain CDR3 comprising SIFYTT (SEQ ID NO:51) or GIFFAI (SEQ ID NO:7); and

(b) a light chain CDR1 comprising RASQSVRSNYLA (SEQ ID NO:8), a light chain CDR2 comprising GASSRAT (SEQ ID NO:9), and a light chain CDR3 comprising QQYSNFPI (SEQ ID NO:10).

2. The isolated polynucleotide of claim 1 , wherein the heavy chain CDR3 comprises SIFYTT (SEQ ID NO:51).

3. The isolated polynucleotide of claim 1 , wherein the heavy chain CDR3 comprises GIFFAI (SEQ ID NO:7).

4. The isolated polynucleotide of claim 1 , wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, or an antibody fragment.

5. A vector comprising the polynucleotide of claim 1 .

6. An isolated cell comprising the vector of claim 5 .

7. An isolated cell comprising the polynucleotide of claim 1 .

8. The isolated polynucleotide of claim 1 , wherein the antibody is a monoclonal antibody.

9. The isolated polynucleotide of claim 1 , wherein the antibody is a humanized antibody.

10. The isolated polynucleotide of claim 1 , wherein the antibody is a human antibody.

11. An isolated polynucleotide encoding an antibody that specifically binds human NOTCH2 and/or NOTCH3, wherein the antibody comprises:

(a) a heavy chain variable region having at least about 90% sequence identity to SEQ ID NO:50, SEQ ID NO:14, or SEQ ID NO:20; and

(b) a light chain variable region having at least about 90% sequence identity to SEQ ID NO:13 or SEQ ID NO:19.

12. The polynucleotide of claim 11 , wherein the antibody comprises:

(a) a heavy chain variable region having at least about 90% sequence identity to SEQ ID NO:50; and

(b) a light chain variable region having at least about 90% sequence identity to SEQ ID NO:13.

13. The polynucleotide of claim 12 , wherein the antibody comprises:

(a) a heavy chain variable region comprising SEQ ID NO:50; and

(b) a light chain variable region comprising SEQ ID NO:13.

14. The polynucleotide of claim 11 , wherein the antibody comprises:

(a) a heavy chain variable region having at least about 90% sequence identity to SEQ ID NO:14; and

(b) a light chain variable region having at least about 90% sequence identity to SEQ ID NO:13.

15. The polynucleotide of claim 14 , wherein the antibody comprises:

(a) a heavy chain variable region comprising SEQ ID NO:14; and

(b) a light chain variable region comprising SEQ ID NO:13.

16. The isolated polynucleotide of claim 11 , wherein the antibody is a monoclonal antibody, a chimeric antibody, a humanized antibody, a human antibody, or an antibody fragment.

17. A vector comprising the polynucleotide of claim 11 .

18. An isolated cell comprising the vector of claim 17 .

19. An isolated cell comprising the polynucleotide of claim 11 .

20. The isolated polynucleotide of claim 11 , wherein the antibody is a monoclonal antibody.

21. The isolated polynucleotide of claim 11 , wherein the antibody is a humanized antibody.

22. The isolated polynucleotide of claim 11 , wherein the antibody is a human antibody.

23. An isolated polynucleotide encoding a polypeptide comprising a sequence selected from the group consisting of SEQ ID NO:50, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:20, and SEQ ID NO:49.

24. The isolated polynucleotide of claim 23 , wherein the polynucleotide encodes a polypeptide comprising the sequence of SEQ ID NO:50 and/or SEQ ID NO:13.

25. An isolated polynucleotide comprising a sequence selected from the group consisting of SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:48, SEQ ID NO:47, SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:15, and SEQ ID NO:17.

26. The isolated polynucleotide of claim 25 , comprising the sequence of SEQ ID NO:58 and/or SEQ ID NO:59.

27. An isolated polynucleotide deposited with ATCC as PTA-9547.

28. An isolated polynucleotide deposited with ATCC as PTA-10170.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2013
From: GURNEY, AUSTIN L.; HOEY, TIMOTHY CHARLES; HTUN VAN DER HORST, EDWARD THEIN; SATO, AARON KEN; LIU, YUAN CHING; BRUHNS, MAUREEN FITCH; LEWICKI, JOHN A.
To: ONCOMED PHARMACEUTICALS, INC.
Reel/Frame 030479/0629 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2013
From: GURNEY, AUSTIN L.; HOEY, TIMOTHY CHARLES; HTUN VAN DER HORST, EDWARD THEIN; SATO, AARON KEN; LIU, YUAN CHING; BRUHNS, MAUREEN FITCH; LEWICKI, JOHN A.
To: ONCOMED PHARMACEUTICALS, INC.
Reel/Frame 030479/0670 →
Continuity (6)
Division 13472305 · May 15, 2012
Division 12499627 · Jul 8, 2009
Provisional Application 61112699 · Nov 7, 2008
Provisional Application 61112701 · Nov 7, 2008
Provisional Application 61079095 · Jul 8, 2008
Related Publication 20130260455A1 · Oct 3, 2013